Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Allosteric and Mutant Specific Inhibitors of IDH1.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

23 citing papers in PubMed, 46 citations in OpenAlex.

1. Machine learning-based QSAR and structure-based virtual screening guided discovery of novel mIDH1 inhibitors from natural products.Journal of computer-aided molecular design · 2025
   Article
2. Site Identification and Next Choice Protocol for Hit-to-Lead Optimization.Journal of chemical information and modeling · 2024
   Article
3. Oxazolidinones as versatile scaffolds in medicinal chemistry.RSC medicinal chemistry · 2023
   Review
4. Differentiating Inhibition Selectivity and Binding Affinity of Isocitrate Dehydrogenase 1 Variant Inhibitors.Journal of medicinal chemistry · 2023
   Article
5. The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancer.Acta pharmaceutica Sinica. B · 2023
   Review
6. Mutated Isocitrate Dehydrogenase (mIDH) as Target for PET Imaging in Gliomas.Molecules (Basel, Switzerland) · 2023
   Review
7. Advances in the Immunotherapeutic Potential of Isocitrate Dehydrogenase Mutations in Glioma.Neuroscience bulletin · 2022
   Review
8. Resistance to the isocitrate dehydrogenase 1 mutant inhibitor ivosidenib can be overcome by alternative dimer-interface binding inhibitors.Nature communications · 2022
   Article
9. QSAR analysis of 3-pyrimidin-4-yl-oxazolidin-2-one derivatives isocitrate dehydrogenase inhibitors using Topomer CoMFA and HQSAR methods.Molecular diversity · 2022
   Article
10. Recent advances of IDH1 mutant inhibitor in cancer therapy.Frontiers in pharmacology · 2022
    Review
11. Roles of metal ions in the selective inhibition of oncogenic variants of isocitrate dehydrogenase 1.Communications biology · 2021
    Article
12. The implications of IDH mutations for cancer development and therapy.Nature reviews. Clinical oncology · 2021
    Review
13. Assessing acquired resistance to IDH1 inhibitor therapy by full-exonCold Spring Harbor molecular case studies · 2021
    Article
14. 2-Hydroxyglutarate in Cancer Cells.Antioxidants & redox signaling · 2020
    Review
15. Isocitrate dehydrogenase variants in cancer - Cellular consequences and therapeutic opportunities.Current opinion in chemical biology · 2020
    Review
16. Water Networks and Correlated Motions in Mutant Isocitrate Dehydrogenase 1 (IDH1) Are Critical for Allosteric Inhibitor Binding and Activity.Biochemistry · 2020
    Article
17. Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics.Frontiers in oncology · 2019
    Review
18. Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Orally Bioavailable and Brain Penetrant Mutant IDH1 Inhibitors.ACS medicinal chemistry letters · 2018
    Article
19. Chromatin dynamics underlying latent responses to xenobiotics.Toxicology research · 2018
    Review
20. Novel Insights for Inhibiting Mutant Heterodimer IDH1Molecular diagnosis & therapy · 2018
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

28 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as